We provide the best possible care. Sustainably in diverse healthcare systems. For a growing number of patients around the world.
Fresenius Medical Care achieves optimal sustainable clinical, quality and technological standards in patient care through our commitment to developing innovative products and therapies.
The unique position of Fresenius Medical Care builds on many years of professional experience and continual innovation. Accordingly, the focus of our research and development effort is to maintain the technological and clinical edge needed to create innovative products and enhanced therapies. Our employees are united in our commitment to providing high-quality products and services and bringing the optimal sustainable medical and professional practices to patient care.
Evolving the standard of kidney disease care is a vital part of our
patient-centric mission at Fresenius Medical Care.
Life can be complex for people living with kidney disease, with unique
challenges for each individual. Addressing this requires a personalized
care approach designed to improve health outcomes that enable greater
independence and quality of life.
Fresenius Medical Care is the world leader in engineering the medical
devices and technologies that make diverse kidney therapies possible.
The size, scale, and expertise of our Care Enablement business is
pioneering the renal care of tomorrow with high-quality MedTech
innovations.
Our Care Delivery business is dedicated to being the kidney care
provider of choice for patients, physicians and payors across the
healthcare spectrum. Supported by our Global Medical Office, we’re
setting new standards of care by generating high-quality patient
outcomes based on a deep understanding of medicine and science.
I am proud to introduce you to this year’s Annual Medical Report, where
we discuss our work in evolving the standard of kidney disease care.
It features insights from some of the foremost experts working in the
field of renal care. They are insights that are powering solutions for
individuals and families who want more and better-quality time to enjoy
the precious gift of life.
When it comes to caring for patients and families, it takes all of us.
Thank you for joining us in leading the way for those who need it most.
Helen Giza
Chief Executive Officer,
Chair of the Management Board
The GMO Emeritus / Emerita program is a distinction awarded to retiring Medical Officers who have the equivalent of 10 years full-time service to FME. They are nominated by the Global Chief Medical Officer and approved by the Management Board for meritorious service to the mission of the company and distinguished contributions to healthcare and society. Medical Officers Emeriti remain connected to FME through ongoing participation in thought leadership and scientific inquiry. Emeriti Officers can be called upon as advisors and subject-matter experts.
Date of Induction | |
Bernard Canaud, MD, PhD | December 31, 2022 |
Allan Collins, MD, FACP | February 17, 2022 |
Adelheid Gauly, PhD, MBA | June 14, 2022 |
Michael J. Lazarus, MD | March 17, 2022 |
Dugan Maddux, MD, PhD | June 30, 2022 |
Norma Ofsthun, PhD | April 28, 2022 |
Thomas J.R. Roy, PhD | July 31, 2022 |
Ted Toffelmire, MD, FRCPC, FACP | December 1, 2023 |
The information in this document is provided as is and no guarantee or warranty is given that the information is fit for any particular purpose. The user thereof uses the information at its sole risk and liability. The opinions expressed in the document are of the authors only and in no way reflect the European Commission’s opinions.
The CONVINCE study was exclusively supported by the European Commission Research & Innovation, Horizon 2020, Call H2020-SC1-2016-2017 under the topic SC1-PM-10-2017: Comparing the effectiveness of existing healthcare interventions in the adult population (grant no 754803).